Aetna Denied Cancer Treatment: Fight Back With These Steps

A cancer treatment denial from Aetna is one of the most devastating outcomes a patient can face. Yet Aetna denies cancer treatment claims at significant rates — including chemotherapy regimens, immunotherapy, radiation protocols, surgical procedures, and clinical trial participation. Most of these denials are legally challengeable, particularly when the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines support the prescribed treatment and the denial reflects an outdated or overly restrictive Clinical Policy Bulletin. The NCCN Compendium is the standard reference in oncology, and an NCCN Category 1 recommendation (based on high-level evidence with uniform NCCN consensus) is the strongest clinical argument against any "experimental" or "not medically necessary" classification from Aetna.

Why Aetna Denies Cancer Treatment Claims

Aetna uses cancer-specific Clinical Policy Bulletins, available at aetna.com/cpb, to govern coverage for specific cancer types and treatment modalities. The most common denial patterns are:

• Off-label chemotherapy denied as "experimental" — Aetna may deny a chemotherapy regimen not FDA-approved for the patient's specific tumor type, even when it carries an NCCN Category 1 or 2A recommendation in the NCCN Compendium.
• Immunotherapy not covered for the specific indication — Checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab) and other immunotherapy agents may be denied when prescribed for NCCN-supported indications that are not FDA-labeled for that specific tumor type or molecular marker.
• Not medically necessary — Aetna's utilization review team determines treatment does not meet internal CPB criteria, often using a policy that lags behind current NCCN guideline updates.
• Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization not obtained — Virtually all chemotherapy and immunotherapy requires prior authorization. Claims without PA, or with expired PA, are denied procedurally.
• Alternative treatment available — Aetna argues a less expensive regimen is an adequate alternative, sometimes substituting generic chemotherapy for newer targeted therapies or immunotherapy without clinical justification.
• Clinical trial treatment not covered — Under ACA §2709, qualified health plans must cover routine patient care costs for patients enrolled in approved clinical trials for cancer or life-threatening conditions. Denial of these costs may be an ACA violation.

How to Appeal an Aetna Cancer Treatment Denial

Step 1: Request the specific CPB and invoke expedited review immediately

Identify the exact CPB Aetna cited (download from aetna.com/cpb) and note when it was last updated — if it predates current NCCN guidelines, that discrepancy is the foundation of your appeal. Under ACA §2719, if your oncologist certifies that delaying treatment would seriously jeopardize your health, Aetna must provide an expedited decision within 72 hours. Request this orally by phone to 1-888-AETNA-AC and confirm in writing simultaneously. Do not wait for the standard 30-day response window.

Step 2: Have your oncologist identify the NCCN guideline recommendation

Your treating oncologist should: identify the applicable NCCN guideline for your cancer type and stage; confirm the evidence category (Category 1 — high-level evidence with uniform consensus; Category 2A — lower-level evidence but uniform consensus); document why the prescribed treatment is appropriate for your specific clinical profile, including any molecular or genomic markers; and explain why alternatives proposed by Aetna are clinically inferior or inappropriate for your case.

Step 3: Gather comprehensive clinical documentation

This includes: pathology reports confirming cancer type, stage, and molecular markers; genomic testing results if applicable (PD-L1 expression for checkpoint inhibitor eligibility, BRCA status for PARP inhibitor eligibility, MSI status); prior treatment history and response; Eastern Cooperative Oncology Group (ECOG) performance status; and the oncologist's written rationale explaining why this specific regimen is the appropriate standard of care.

Step 4: Write the internal appeal letter citing NCCN guidelines directly

Quote the NCCN guideline recommendation with its evidence category. Address the specific CPB criteria and demonstrate how your case meets them. For "experimental" classifications of NCCN-recommended treatments, argue that the NCCN Compendium is an accepted standard reference — one Aetna's own CPBs cite — and that Aetna's CPB has not kept pace with the current NCCN update. For clinical trial care, cite ACA §2709 explicitly. Invoke ACA §2719 for appeal rights and ERISA §1133 for claims file access. File within 180 days of the denial.

Step 5: Request peer-to-peer review with Aetna's oncology medical director

Your treating oncologist calls Aetna's medical director at 1-888-MD-AETNA. In oncology denials, peer-to-peer review by a board-certified oncologist on Aetna's side frequently results in reversal when the NCCN recommendation is clearly applicable and the treating oncologist can discuss the clinical specifics.

Step 6: Request External Independent Review: Complete Guide" class="auto-link">external review without delay if the internal appeal is denied

Do not wait — cancer treatment delays have direct clinical consequences. External reviewers apply clinical standards, not Aetna's proprietary CPB criteria. NCCN guideline-supported cancer treatments are overturned at high rates on external review. File the external review request on the day of the internal appeal denial.

What to Include in Your Appeal

• Denial letter with specific CPB provision and denial reason, plus the relevant Aetna CPB for the cancer type downloaded from aetna.com/cpb
• NCCN Clinical Practice Guideline recommendation with evidence category (Category 1 or 2A preferred) and the applicable NCCN Compendium listing if off-label
• Pathology report with cancer type, stage, and molecular markers, plus genomic or biomarker testing results if applicable (PD-L1, BRCA, MSI)
• Treating oncologist's letter of medical necessity citing NCCN guidelines, the patient's ECOG performance status, and explanation of why Aetna's proposed alternative is clinically inferior
• Expedited review request confirmation (for urgent denials where treatment delay would seriously jeopardize health) and peer-to-peer review request

Fight Back With ClaimBack

Aetna cancer treatment denials frequently cite CPBs that lag behind current NCCN guidelines. When NCCN-supported treatments are denied as "experimental" or "not medically necessary," well-documented appeals succeed regularly. ClaimBack generates a professional, Aetna-specific appeal letter in 3 minutes — act now before treatment delays become irreversible. Start your free claim analysis → Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal